Manchester Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Manchester Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-423	Closed	-$55.8K	–	1253
2025 Q1	$55.8K	Sell	423 -11	-3%	-$1.37K	0.01%	527
2024 Q4	$36.2K	Hold	434	–	–	﹤0.01%	607
2024 Q3	$31.8K	Hold	434	–	–	﹤0.01%	624
2024 Q2	$29.7K	Buy	+434	New	+$30.1K	﹤0.01%	597

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Manchester Capital Management's ITCI Position: Q2 2025 in Review

Manchester Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 423 shares — an estimated $55.8K sold.

Manchester Capital Management first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $55.8K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Manchester Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Manchester Capital Management sold 423 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $55.8K.
Manchester Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Manchester Capital Management's Intra-Cellular Therapies Inc. position peaked at $55.8K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Manchester Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.